Wasatch Advisors Inc Ligand Pharmaceuticals Inc Transaction History

Wasatch Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$94.99 - $151.56 $18.5 Million - $29.6 Million	-195,197 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$127.69 - $165.85 $2.67 Million - $3.46 Million	-20,875 Reduced 9.66%	195,197 $30.2 Million
Q3 2021 Nov 12, 2021	BUY	$102.33 - $144.73 $164,239 - $232,291	1,605 Added 0.75%	216,072 $30.1 Million
Q2 2021 Aug 12, 2021	BUY	$113.03 - $155.64 $52,898 - $72,839	468 Added 0.22%	214,467 $28.1 Million
Q1 2021 May 10, 2021	SELL	$99.52 - $215.83 $95 Million - $206 Million	-954,998 Reduced 81.69%	213,999 $32.6 Million
Q4 2020 Feb 12, 2021	BUY	$80.55 - $106.05 $4.4 Million - $5.8 Million	54,654 Added 4.9%	1,168,997 $116 Million
Q3 2020 Nov 10, 2020	BUY	$89.56 - $126.72 $12.8 Million - $18.1 Million	142,920 Added 14.71%	1,114,343 $106 Million
Q2 2020 Aug 12, 2020	BUY	$68.28 - $123.65 $19.2 Million - $34.8 Million	281,568 Added 40.82%	971,423 $109 Million
Q1 2020 May 08, 2020	BUY	$63.37 - $107.88 $43.7 Million - $74.4 Million	689,855 New	689,855 $50.2 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.07B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.